CB-010 ANTLER Dose-Expansion Cohort — ASGCT 2026
CB-010 dose-expansion data at ASGCT 2026 — bridge between the prior dataset and the year-end Phase 1 update. Watch: CR rate, CR durability, CRS / ICANS incidence.
What’s at stake
CB-010 is an allogeneic (off-the-shelf) CAR-T cell therapy developed by Caribou Biosciences for relapsed or refractory B-cell non-Hodgkin lymphoma. Using Caribou's chRDNA gene-editing platform, donor T cells are engineered to express a CD19-targeting chimeric antigen receptor and edited to reduce immune markers that would trigger rejection in a different patient, enabling a single manufacturing run to supply multiple patients. Unlike autologous CAR-T therapies (Yescarta, Breyanzi), which require 3–4 weeks of custom manufacturing per patient, CB-010 is available immediately as a stockpiled product; Phase 1 dose-expansion data are being presented in 2026.
No primer in glossary yet.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| BEAM-101 | BEAM | cell therapy | base editing of HBG1/2 to reactivate fetal hemoglobin | READOUT · Dec 26 | |
| reni-cel | EDIT | cell therapy | CRISPR/Cas12a HBG1/2 promoter edit | CONFERENCE · May 26 | |
| CASGEVYexagamglogene autotemcel | CRSP | cell therapy | CRISPR/Cas9 BCL11A enhancer edit | CONFERENCE · Dec 26 | |
| JAKAFIruxolitinib | INCY | small molecule | JAK1/JAK2 inhibitor | READOUT · Sep 26 |
Disclosure trail
- Mar 12, 2026·1mo agopinned · highest confidenceHIGH confPRWINDOWtop claimMAY–MAY2026
“Caribou will present an updated dose-expansion dataset from the ANTLER Phase 1 study of CB-010 at the ASGCT 28th Annual Meeting (May 4–8, 2026, San Diego).”
conf 91%via llm